Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive status confers therapeutic sensitivity to Paclitaxel, Trastuzumab in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved paclitaxel (80) in combination with trastuzumab therapy - 7 day (12 weeks) for reimbursement as a treatment option for the adjuvant treatment of HER2 positive, node-negative breast cancer of tumor size <= 3 cm.
This statement is based on a regulatory approval from the Health Service Executive:
Adjuvant Treatment of HER2 positive, Node-Negative Breast Cancer of tumour size <= 3cm.